Recent developments highlight Vivani Medical's progress in clinical trials, strategic partnerships, financing activities, and corporate governance changes.

• Vivani Medical is preparing for an August 2026 human trial of its semaglutide implant following a deal with Novo Nordisk to evaluate the drug implant NPM-139 [N1][N3].
• The company secured funding for the GLP-1 implant trial as of March 2026 [N4].
• Vivani priced a common stock offering at $1.48 per share in January 2026 to support its operations [N5].
• Vivani's subsidiary Cortigent is presenting advanced brain-implant technology at NANS 2026 and is planned for spin-off as an independent Nasdaq company [N6][N8].
• Anthony Baldor was appointed as CFO in June 2025, succeeding Brigid Makes [N7].
• The company reported successful initial data from the LIBERATE-1™ study and secured $3 million in equity financing in May 2025 [N8].

Vivani Medical's collaboration with Novo Nordisk and progress in clinical trials for the semaglutide implant could enhance its credibility and potential market access. The successful spin-off of Cortigent may unlock value and allow focused development of brain-implant technologies. Strong liquidity and recent equity financing provide resources to advance clinical programs and regulatory submissions.

The company faces risks typical of early-stage medical technology firms, including the need for substantial additional capital, regulatory approval uncertainties, and potential delays in clinical development. Market acceptance of implantable drug delivery systems and competition from established pharmaceutical and device companies also present challenges. External factors such as healthcare policy changes and geopolitical disruptions could impact operations and funding.

Vivani Medical's moat is based on its proprietary implantable drug delivery technology platform and strategic collaboration with Novo Nordisk, a leading pharmaceutical company. The company's focus on innovative, long-acting implantable therapies for chronic conditions such as obesity and diabetes positions it in a niche with high barriers to entry due to regulatory complexity, technological challenges, and the need for clinical validation.

• Capital Requirements and Financing Risk: Vivani Medical requires substantial additional financing to pursue its business objectives. Failure to obtain capital on acceptable terms could delay or limit product development and commercialization efforts [S2].
• Regulatory and Clinical Trial Risks: The company operates in a highly regulated industry. Delays or failures in clinical trials or regulatory approvals could materially affect business prospects [S1][S2].
• Operational Risks from External Factors: Global health epidemics, geopolitical conflicts, and government shutdowns could disrupt clinical trials, regulatory reviews, and supply chains, adversely impacting operations [S1][S2].

• Vivani Medical, Inc. is a medical technology company developing implantable drug delivery systems.
• The company is developing a semaglutide drug implant called NPM-139 for weight management and related indications.
• Vivani Medical has entered into a deal with Novo Nordisk to evaluate the semaglutide drug implant NPM-139, indicating collaboration with a major pharmaceutical company [N3].
• The company is conducting human clinical trials for its GLP-1 implant, with a human trial eyed for August 2026 [N1].
• Vivani Medical secured funding for the GLP-1 implant trial as of March 2026 [N4].
• The company has a subsidiary, Cortigent, which develops advanced brain-implant technology and is planned for spin-off as an independent Nasdaq company in 2025 [N6][N8].
• Vivani Medical reported successful initial data from the LIBERATE-1™ study and secured $3 million in equity financing as of May 2025 [N8].
• The company appointed Anthony Baldor as CFO in June 2025 [N7].
• Financial snapshot as of June 30, 2026, shows cash and equivalents of $19.9 million, current assets of $21.6 million, current liabilities of $6.7 million, resulting in a current ratio of 3.25 and cash ratio of 2.99, indicating strong liquidity [S2].
• Net loss for the quarter ended June 30, 2026, was $6.37 million with basic and diluted EPS of -$0.07 [S2].
• The company completed a common stock offering priced at $1.48 per share in January 2026 [N5].
• Vivani Medical operates in a highly regulated industry with risks related to regulatory approvals, capital requirements, and potential disruptions from global health or geopolitical events [S1][S2].